Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
56.00
+18.93 (51.07%)
At close: Feb 10, 2026, 4:00 PM EST
58.75
+2.75 (4.91%)
After-hours: Feb 10, 2026, 7:50 PM EST
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,026,230
Profits / Employee
-$1,979,279
Market Cap
1.14B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | 718 | -5 | -0.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| Phathom Pharmaceuticals | 427 |
| Vir Biotechnology | 408 |
| Pharming Group | 404 |
| UroGen Pharma | 287 |
| Geron | 229 |
| Sana Biotechnology | 194 |
| ORIC Pharmaceuticals | 106 |
NKTR News
- 3 hours ago - Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript - Seeking Alpha
- 4 hours ago - Nektar Therapeutics Announces Proposed Public Offering - PRNewsWire
- 13 hours ago - New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing - PRNewsWire
- 1 day ago - Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 - PRNewsWire
- 11 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 26 days ago - Nektar.io Introduces DIRT: Materials Management for the Construction Industry - Newsfile Corp
- 7 weeks ago - Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg - Seeking Alpha
- 2 months ago - Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript - Seeking Alpha